

# An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB

NCT06488924

---

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	JCR Pharmaceuticals Co., Ltd.
Enrollment	10 participants

## Key Eligibility Criteria

---

### Inclusion (2)

- Chronological age of  $\leq 18$  years
- Confirmed diagnosis of MPS IIIB

### Exclusion (8)

- Prior experience to gene therapy or HSCT with successful engraftment
- Past use of another investigational drug or product in last 4 months or 5 half-lives (whichever is longer) before signing ICF
- Current participation in a clinical trial or past participation (within 30 days of enrolment into this study) in a study involving invasive procedures
- Past use of Genistein or Kineret (anakinra) within 4 months before signing ICF
- Serious drug allergy or hypersensitivity
- ... and 3 more (see full listing online)

## Locations (3 total)

---

Hiroshima University Hospital, Hiroshima, Japan  
University of the Ryukyus Hospital, Okinawa, Japan  
National Center for Child Health and Development, Tokyo, Japan